TY - JOUR
T1 - Epiretinal membranes in uveitic macular edema
T2 - Effect on vision and response to therapy
AU - Lehpamer, Brian
AU - Moshier, Erin
AU - Pahk, Patricia
AU - Goldberg, Naomi
AU - Ackert, Jessica
AU - Godbold, James
AU - Jabs, Douglas A.
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Financial disclosures: Douglas A. Jabs: Abbott Laboratories, Applied Genetic Technologies Corporation (AGTC), Alcon Laboratories, Corcept Therapeutics, GenenTech, Inc, Genzyme Corporation, GlaxoSmithKline, Novartis Pharmaceutical Corp, Regeneron, and Santen Pharmaceuticals. Funding support: supported in part by an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York. Supported in part by award number UL1RR029887 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Contributions of authors: design of the study (D.A.J.); conduct of the study (B.L., P.P., N.G., J.A., D.A.J.); collection of the data (B.L., P.P.); management of the data (B.L.); analysis of the data (B.L., E.M., P.P., D.A.J.); interpretation of the data (B.L., E.M., P.P., D.A.J.); preparation of the manuscript (B.L., P.P., J.G.); review of the manuscript (J.G., P.P., N.G., J.A., D.A.J.); approval of the manuscript (B.L., E.M., P.P., J.G., J.A., J.G., D.A.J.).
PY - 2014/5
Y1 - 2014/5
N2 - Purpose To evaluate the effects of epiretinal membranes on the response of uveitic macular edema to therapy and on visual acuity outcomes. Design Retrospective case series. Methods One hundred four eyes of 77 patients with uveitic macular edema were identified at a tertiary care center. Epiretinal membranes were diagnosed when identified by 2 investigators' grading of spectral-domain optical coherence tomography and scored for the presence or absence of surface wrinkling. Outcomes included best-corrected visual acuity, central subfield thickness, and rates of macular edema improvement (>20% reduction in central subfield thickness) and resolution (reduction of central subfield thickness to <315 μm) at 3 and 6 months follow-up. Results Seventy-two eyes of 59 patients had an epiretinal membrane on presentation. Eyes without epiretinal membranes and with epiretinal membranes without surface wrinkling were not significantly different at presentation or at 3 and 6 months follow-up. Conversely, eyes with an epiretinal membrane with retinal surface wrinkling had a greater proportion of eyes with 20/200 or worse visual acuity at presentation, and had worse mean acuities at 3 months (20/94 vs 20/35 for eyes without an epiretinal membrane, P =.002) and at 6 months follow-up (20/110 vs 20/36 for eyes without an epiretinal membrane, P =.02). At 6 months of follow-up the mean central subfield thicknesses were: eyes without an epiretinal membrane, 338 ± 23 μm; and eyes with an epiretinal membrane and surface wrinkling, 405 ± 22 μm (P =.05). Conclusions In eyes with epiretinal membranes and retinal surface wrinkling, uveitic macular edema had a poorer visual acuity response to medical therapy and thicker maculae at 6 months.
AB - Purpose To evaluate the effects of epiretinal membranes on the response of uveitic macular edema to therapy and on visual acuity outcomes. Design Retrospective case series. Methods One hundred four eyes of 77 patients with uveitic macular edema were identified at a tertiary care center. Epiretinal membranes were diagnosed when identified by 2 investigators' grading of spectral-domain optical coherence tomography and scored for the presence or absence of surface wrinkling. Outcomes included best-corrected visual acuity, central subfield thickness, and rates of macular edema improvement (>20% reduction in central subfield thickness) and resolution (reduction of central subfield thickness to <315 μm) at 3 and 6 months follow-up. Results Seventy-two eyes of 59 patients had an epiretinal membrane on presentation. Eyes without epiretinal membranes and with epiretinal membranes without surface wrinkling were not significantly different at presentation or at 3 and 6 months follow-up. Conversely, eyes with an epiretinal membrane with retinal surface wrinkling had a greater proportion of eyes with 20/200 or worse visual acuity at presentation, and had worse mean acuities at 3 months (20/94 vs 20/35 for eyes without an epiretinal membrane, P =.002) and at 6 months follow-up (20/110 vs 20/36 for eyes without an epiretinal membrane, P =.02). At 6 months of follow-up the mean central subfield thicknesses were: eyes without an epiretinal membrane, 338 ± 23 μm; and eyes with an epiretinal membrane and surface wrinkling, 405 ± 22 μm (P =.05). Conclusions In eyes with epiretinal membranes and retinal surface wrinkling, uveitic macular edema had a poorer visual acuity response to medical therapy and thicker maculae at 6 months.
UR - http://www.scopus.com/inward/record.url?scp=84898848675&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2014.01.020
DO - 10.1016/j.ajo.2014.01.020
M3 - Article
C2 - 24487049
AN - SCOPUS:84898848675
SN - 0002-9394
VL - 157
SP - 1048
EP - 1055
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -